PDF icon Download PDF
Dtsch Med Wochenschr 2004; 129(18): 1027-1031
DOI: 10.1055/s-2004-824835
Übersichten
Gastroenterologie / Pharmakologie
© Georg Thieme Verlag Stuttgart · New York

Gastrointestinale Nebenwirkungen von Medikamenten[1]

Gastrointestinal side effects of drugsD. Jaspersen1 , K.-U Petersen2
  • 1Medizinische Klinik II, Klinikum Fulda gAG
  • 2Institut für Pharmakologie und Toxikologie, RWTH Aachen
Further Information

Publication History

eingereicht: 27.8.2003

akzeptiert: 15.1.2004

Publication Date:
20 July 2004 (online)

Also available ateRef
   Permissions and Reprints
Preview

Unerwünschte Arzneimittelwirkungen (UAW) können im gesamten Verdauungstrakt auftreten. Wichtige Beispiele im oberen Intestinaltrakt sind Schleimhautschäden durch Bisphosphonate und nichtsteroidale Antirheumatika (NSAR); die letztgenannten schädigen nicht selten auch Dünn- und Dickdarm. Häufige Nebenwirkung einer antibiotischen Behandlung ist die Enterokolitis; zahlreiche Pharmaka wie Diuretika können Ursache einer akuten Pankreatitis sein. In diesem Beitrag sollen die wesentlichen UAW im Gastrointestinaltrakt und ihre Therapie diskutiert werden.

1 Herrn Prof. Dr. J. F. Riemann gewidmet

Literatur

  • 1 Ablin D S, Ziegler M. Ulcerative type of colitis associated with the use of high strength pancreatic enzyme supplements in cystic fibrosis.  Pediatr Radiol. 1995;  25 113-115
    Search in Google Scholar
  • 2 Allen M, Mellow M, Robinson M G, Orr W C. Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function.  Aliment Pharmacol Ther. 1987;  1 153-159
    Search in Google Scholar
  • 3 Allison M C, Howatson A G, Torrance C J. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs.  N Engl J Med. 1992;  327 749-754
    Search in Google Scholar
  • 4 Andersen V, Sonne J, Andersen M. Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999.  Eur J Clin Pharmacol. 2001;  57 517-521
    Search in Google Scholar
  • 5 Arzneimittelkommission der Deutschen Ärzteschaft . Zur Sicherheit von COX-2-Inhibitoren.  Dtsch Ärztebl. 2002;  99 1291-1292
    Search in Google Scholar
  • 6 Ballinger A B, Smith G. COX-2 vs NSAIDs: gastrointestinal damage and prevention.  Exp Opin Pharmacother. 2001;  2 31-40
    Search in Google Scholar
  • 7 Bansi D S, Price A, Russell C, Sarner M. Fibrosing colonopathy in an adult owing to overuse of pancreatic enzyme supplements.  Gut. 2000;  46 283-285
    Search in Google Scholar
  • 8 Bombardier C, Laine L, Reicin A. et al. VIGOR study group . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.  N Engl J Med. 2000;  343 1520-1528
    Search in Google Scholar
  • 9 Boyce H W. Drug-induced esophageal damage: diseases of medical progress.  Gastrointest Endosc. 1998;  47 547-550
    Search in Google Scholar
  • 10 Byrne M F, McGuiness J, Smyth C M. et al . Nonsteroidal anti-inflammatory drug-induced diaphragms and ulceration in the colon.  Eur J Gastroenterol Hepatol. 2002;  14 1265-1269
    Search in Google Scholar
  • 11 Chan F KL, Chung S CS, Suen R N. et al . Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.  N Engl J Med. 2001;  344 967-973
    Search in Google Scholar
  • 12 Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza G. et al . Risk factors for esophageal candidiasis.  Eur J Clin Microbiol Infect Dis. 2000;  19 96-100
    Search in Google Scholar
  • 13 De Abajo F J, Garcia Rodriguez L A, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population-based case-control study.  Br Med J. 1999;  319 1106-1109
    Search in Google Scholar
  • 14 El-Serag H B, Sonnenberg A. Association of esophagitis and esophageal strictures with diseases treated with non-steroidal anti-inflammatory drugs.  Am J Gastroenterol. 1997;  92 52-56
    Search in Google Scholar
  • 15 De Groen P C, Lubbe D F, Laurence C B. Esophagitis associated with the use of alendronate.  N Engl J Med. 1996;  335 1016-1021
    Search in Google Scholar
  • 16 Garcia Rodriguez L A, Hernandez-Diaz S, De Abajo F J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.  Br J Clin Pharmacol. 2001;  52 563-571
    Search in Google Scholar
  • 17 Garcia Rodriguez L A, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs.  Epidemiology. 2001;  12 570-576
    Search in Google Scholar
  • 18 Hawkey C J, Langman M JS. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.  Gut. 2003;  52 600-608
    Search in Google Scholar
  • 19 Ishikawa H, Iwakiri K, Sugiura T, Kobayashi M. Effect of nifedipine administration (10 mg) on esophageal acid exposure.  J Gastroenterol. 2000;  35 43-46
    Search in Google Scholar
  • 20 Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management.  Drug Saf. 2000;  22 237-249
    Search in Google Scholar
  • 21 Jaspersen D. Extragastrale Nebenwirkungen nicht steroidaler Antirheumatika.  Dtsch Med Wochenschr. 1998;  132 669-673
    Search in Google Scholar
  • 22 Kikendall J W, Mellow M H. Effect of sublingual nitroglycerin and long-acting nitrate preparations on esophageal motility.  Gastroenterology. 1980;  79 703-706
    Search in Google Scholar
  • 23 Kikendall J W. Pill esophagitis.  J Clin Gastroenterol. 1999;  28 298-305
    Search in Google Scholar
  • 24 Langman M J, Weil J, Wainwright G HT P. et al . Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.  Lancet. 1994;  343 1075-1078
    Search in Google Scholar
  • 25 Lankisch P G, Droege M, Gottesleben F. Drug-induced acute pancreatitis: incidence and severity.  Gut. 1995;  37 565-567
    Search in Google Scholar
  • 26 Larkai E N, Smith J L, Lidsky M D, Graham D Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.  Am J Gastroenterol. 1987;  82 1153-1158
    Search in Google Scholar
  • 27 Lewis S C, Langman M J, Laporte J R, Matthews J N, Rawlins M D, Wiholm B E. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data.  Br J Clin Pharmacol. 2002;  54 320-326
    Search in Google Scholar
  • 28 Limmer S, Ittel T H, Wietholz H. Sekundär- und Primärprophylaxe der ASS-/NSAR-Gastropathie: Eine Übersicht anhand vier klinischer Szenarien.  Z Gastroenterol. 2003;  41 719-728
    Search in Google Scholar
  • 29 Lloyd-Still J D. Cystic fibrosis and colonic strictures: a new ‘iatrogenic’ disease.  J Clin Gastroenterol. 1995;  21 2-5
    Search in Google Scholar
  • 30 Mallory A, Kern F. Drug-induced pancreatitis: a critical review.  Gastroenterology. 1980;  78 813-820
    Search in Google Scholar
  • 31 Makins R, Ballinger A. Gastrointestinal side effects of drugs. Expert Opin.  Drug Saf. 2003;  2 421-429
    Search in Google Scholar
  • 32 McArthur K E. Drug-induced pancreatitis.  Aliment Pharmacol Ther. 1996;  10 23-27
    Search in Google Scholar
  • 33 Milminick T, Frick T W. Drug-induced pancreatitis.  Drug Saf. 1996;  14 406-409
    Search in Google Scholar
  • 34 Nassar N N, Gregg C R. Oesophageal infections.  Curr Treat Options Gastroenterol. 1998;  1 56-63
    Search in Google Scholar
  • 35 Pemberton J. Oesophageal obstruction and ulceration caused by oral potassium therapy.  Br Heart J. 1970;  32 267-268
    Search in Google Scholar
  • 36 Petersen K U, Jaspersen D. Medication-induced esophageal disorders. Expert Opin.  Drug Saf. 2003;  5 1-13
    Search in Google Scholar
  • 37 Ratnaike R N, Jones T E. Mechanisms of drug-induced diarrhoea in the elderly.  Drugs Aging. 1998;  13 245-253
    Search in Google Scholar
  • 38 Rünzi M, Layer P. Drug-associated pancreatitis: facts and fiction.  Pancreas. 1996;  13 100-109
    Search in Google Scholar
  • 39 Simon L S, Weaver A L, Graham D Y. et al . Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.  JAMA. 1999;  282 1921-1928
    Search in Google Scholar
  • 40 Silverstein F E, Faich G, Goldstein. et al . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.  JAMA. 2000;  284 1247-1255
    Search in Google Scholar
  • 41 Smale S, Tibble J, Sigthorsson G, Bjarnason I. Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine.  Best Pract Res Clin Gastroenterol. 2001;  15 723-738
    Search in Google Scholar
  • 42 Smyth R L, van Velzen D, Smyth R A. et al . Strictures of the ascending colon in cystic fibrosis and high-strength pancreatic enzyme supplements.  Lancet. 1994;  343 85-86
    Search in Google Scholar
  • 43 Stein J, Schröder O. Antibiotikaassoziierte Kolitis - Eine relevante Krankheit?. Urban und Schwarzenberg, München In: Klinik der Gegenwart, Gerock W, Schöllermich J (HRSG) 1997: 1-26
    Search in Google Scholar
  • 44 Thumshirn M, Fried M. Prophylaxe und Therapie NSAR-induzierter Ulzera: ein Update.  Dtsch med Wochenschr. 2000;  125 975-978
    Search in Google Scholar
  • 45 Vanek V W, Al-Salti M. Acute pseudo-obstruction of the colon (Ogilvie’s syndrome). An analysis of 400 cases.  Dis Colon Rectum. 1986;  29 203-210
    Search in Google Scholar
  • 46 Van Velzen D, Ball L M, Dezfulian A R, Southgate A, Howard C V. Comparative and experimental pathology of fibrosing colonopathy.  Postgrad Med J. 1996;  72 S39-S48
    Search in Google Scholar
  • 47 Wolfe M M, Lichtenstein D R, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs.  N Engl J Med. 1999;  340 1888-1899
    Search in Google Scholar
  • 48 Wright J M. The double-edged sword of COX-2 selective NSAIDs.  Can Med Assoc J. 2002;  167 1131-1137
    Search in Google Scholar

1 Herrn Prof. Dr. J. F. Riemann gewidmet

Prof. Dr. Daniel Jaspersen

Klinikum Fulda gAG, Med. Klinik II

Pacelliallee 4

36043 Fulda

Email: d.jaspersen.medII@klinikum-fulda.de